JP2018502115A - ナチュラルキラー細胞及びその使用 - Google Patents

ナチュラルキラー細胞及びその使用 Download PDF

Info

Publication number
JP2018502115A
JP2018502115A JP2017534937A JP2017534937A JP2018502115A JP 2018502115 A JP2018502115 A JP 2018502115A JP 2017534937 A JP2017534937 A JP 2017534937A JP 2017534937 A JP2017534937 A JP 2017534937A JP 2018502115 A JP2018502115 A JP 2018502115A
Authority
JP
Japan
Prior art keywords
cells
medium
concentration
present
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017534937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502115A5 (enExample
Inventor
マーフィー ブライアン
マーフィー ブライアン
ボスキナリアン‐ベルセ バネッサ
ボスキナリアン‐ベルセ バネッサ
ノードバーグ アンドレア
ノードバーグ アンドレア
ウィルソン キース
ウィルソン キース
カング リン
カング リン
Original Assignee
アントフロゲネシス コーポレーション
アントフロゲネシス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントフロゲネシス コーポレーション, アントフロゲネシス コーポレーション filed Critical アントフロゲネシス コーポレーション
Publication of JP2018502115A publication Critical patent/JP2018502115A/ja
Publication of JP2018502115A5 publication Critical patent/JP2018502115A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017534937A 2014-12-31 2015-12-30 ナチュラルキラー細胞及びその使用 Pending JP2018502115A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098560P 2014-12-31 2014-12-31
US62/098,560 2014-12-31
PCT/US2015/068055 WO2016109661A1 (en) 2014-12-31 2015-12-30 Natural killer cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020213684A Division JP2021072786A (ja) 2014-12-31 2020-12-23 ナチュラルキラー細胞及びその使用

Publications (2)

Publication Number Publication Date
JP2018502115A true JP2018502115A (ja) 2018-01-25
JP2018502115A5 JP2018502115A5 (enExample) 2019-02-21

Family

ID=56285039

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017534937A Pending JP2018502115A (ja) 2014-12-31 2015-12-30 ナチュラルキラー細胞及びその使用
JP2020213684A Pending JP2021072786A (ja) 2014-12-31 2020-12-23 ナチュラルキラー細胞及びその使用
JP2022176993A Pending JP2023022037A (ja) 2014-12-31 2022-11-04 ナチュラルキラー細胞及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020213684A Pending JP2021072786A (ja) 2014-12-31 2020-12-23 ナチュラルキラー細胞及びその使用
JP2022176993A Pending JP2023022037A (ja) 2014-12-31 2022-11-04 ナチュラルキラー細胞及びその使用

Country Status (12)

Country Link
US (2) US20180008637A1 (enExample)
EP (1) EP3240552A4 (enExample)
JP (3) JP2018502115A (enExample)
KR (2) KR20230146101A (enExample)
CN (1) CN107405364A (enExample)
AU (2) AU2015374055A1 (enExample)
BR (1) BR112017014269A2 (enExample)
CA (1) CA2972662A1 (enExample)
EA (1) EA201791443A1 (enExample)
IL (1) IL253248A0 (enExample)
NZ (1) NZ733213A (enExample)
WO (1) WO2016109661A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521262A (ja) * 2018-02-20 2021-08-26 ウニヴェルシテ・ドゥ・モントリオール 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
ES2980858T3 (es) * 2015-09-15 2024-10-03 Stichting Radboud Univ Medisch Centrum Método mejorado para la expansión ex vivo de HSPC CD34+ en células NK usando un antagonista del receptor de aril hidrocarburos
JP2018535666A (ja) * 2015-10-15 2018-12-06 セルラリティ インコーポレイテッド ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用
US20200179341A1 (en) * 2016-11-04 2020-06-11 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor
US20180273903A1 (en) * 2016-12-30 2018-09-27 Celularity, Inc. Genetically modified natural killer cells
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
JP7269917B2 (ja) * 2017-08-17 2023-05-09 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
KR102167548B1 (ko) * 2017-09-21 2020-10-19 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
WO2019059713A2 (ko) * 2017-09-21 2019-03-28 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
US12304962B2 (en) 2018-05-30 2025-05-20 Glycostem Therapeutics B.V. CAR NK cells
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
CA3112951A1 (en) * 2018-10-01 2020-04-09 Universiteit Gent Accelerated human hematopoietic stem cell differentiation towards mature natural killer cells with enhanced antibody-dependent cytotoxic activity
CN109294985B (zh) * 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法
CN113454207A (zh) * 2018-11-30 2021-09-28 细胞结构公司 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞
KR20210114422A (ko) * 2018-12-21 2021-09-23 스템셀 테크놀러지스 캐나다 인크. 자연살해세포의 분화를 위한 배지 및 방법
JP7335001B2 (ja) * 2019-01-18 2023-08-29 アセポディア バイオテクノロジーズ リミテッド 新規ｃｄ１６＋ナチュラルキラーおよびｃｄ１６＋ナチュラルキラー細胞の培養方法
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
KR102298640B1 (ko) * 2019-03-28 2021-09-07 한국생명공학연구원 Car 유전자가 도입된 nk 세포의 제조방법 및 그의 용도
CN110079529A (zh) * 2019-04-28 2019-08-02 成都美杰赛尔生物科技有限公司 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途
US20220265712A1 (en) * 2019-06-14 2022-08-25 Celularity Inc. Populations of natural killer cells for treating cancers
CN113652393B (zh) * 2020-05-12 2023-08-15 内蒙古大学 一种提高牛胚胎干细胞多能性的方法
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN113046314B (zh) * 2021-03-30 2022-11-25 中国科学技术大学 一种人脐血或骨髓造血干细胞体外诱导扩增蜕膜样自然杀伤细胞的方法
CN113337466B (zh) * 2021-07-13 2023-03-24 杭州原生生物科技有限公司 一种无血清nk分化培养基及其制备方法
CN115381959A (zh) * 2022-09-30 2022-11-25 上海纳米技术及应用国家工程研究中心有限公司 一种治疗肝癌的联合用药

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140023626A1 (en) * 2012-07-23 2014-01-23 Gamida Cell Ltd. Enhancement of Natural Killer (NK) Cell Proliferation and Activity
WO2014028453A2 (en) * 2012-08-13 2014-02-20 Anthrogenesis Corporation Natural killer cells and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3358007A1 (en) * 2010-07-13 2018-08-08 Celularity, Inc. Methods of generating natural killer cells
KR102098122B1 (ko) * 2012-01-27 2020-04-07 유니버시떼 드 몬트리얼 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도
PL2812011T3 (pl) * 2012-02-08 2020-06-29 Glycostem Therapeutics B.V. Różnicowanie komórek NK z komórek hematopoetycznych CD34<sup>+</sup> ex vivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140023626A1 (en) * 2012-07-23 2014-01-23 Gamida Cell Ltd. Enhancement of Natural Killer (NK) Cell Proliferation and Activity
WO2014028453A2 (en) * 2012-08-13 2014-02-20 Anthrogenesis Corporation Natural killer cells and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 122, no. 21, JPN6019050599, 2013, pages 1656, ISSN: 0004337089 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521262A (ja) * 2018-02-20 2021-08-26 ウニヴェルシテ・ドゥ・モントリオール 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大
JP7467358B2 (ja) 2018-02-20 2024-04-15 ウニヴェルシテ・ドゥ・モントリオール 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大
US12011460B2 (en) 2018-02-20 2024-06-18 Universite De Montreal Expansion of NK and DC cells in vivo mediating immune response

Also Published As

Publication number Publication date
US20200330516A1 (en) 2020-10-22
CA2972662A1 (en) 2016-07-07
NZ733213A (en) 2022-10-28
KR20230146101A (ko) 2023-10-18
JP2023022037A (ja) 2023-02-14
WO2016109661A1 (en) 2016-07-07
KR20170098938A (ko) 2017-08-30
AU2021282387A1 (en) 2021-12-23
EA201791443A1 (ru) 2018-01-31
EP3240552A1 (en) 2017-11-08
JP2021072786A (ja) 2021-05-13
US20180008637A1 (en) 2018-01-11
IL253248A0 (en) 2017-08-31
AU2015374055A1 (en) 2017-07-20
BR112017014269A2 (pt) 2018-03-27
CN107405364A (zh) 2017-11-28
EP3240552A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
US20230142803A1 (en) Natural killer cells and ilc3 cells and uses thereof
JP2023022037A (ja) ナチュラルキラー細胞及びその使用
US20220259563A1 (en) Methods of generating natural killer cells
AU2022200976A1 (en) Natural killer cells and uses thereof
US20230028680A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
AU2021240151A1 (en) Methods of generating natural killer cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200318

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200901

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201223

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20210112

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210112

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20210302

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20210406

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210406